Method for treating animals at dioxine intoxication

FIELD: veterinary science.

SUBSTANCE: in case of dioxine intoxication animals should be prescribed with dimephosphon at the dosage of about 50-150 mg/kg body weight daily for 10-30 d. The innovation provides decreased embryonic lethality in animals.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

 

The invention relates to the field of veterinary medicine, in particular to methods for treating animals in toxicosis.

A large number of toxicants anthropogenic origin were the most dangerous polychlorinated dibenzodioxin, among which the most toxic is 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-THDC), referred to as the generic term dioxin.

Dioxins are the most toxic of the universal poison that affects virtually all organ systems, primarily the immune system and is functionally related to the blood system.

The main danger of dioxins is their sverhsostoyatelnosti and ability to cause long-term consequences in the form of immunosuppressive, mutagenic and embryotoxic effects. In the process of accumulation of each new portion of dioxin is more toxic than the previous one.

Specific treatment of poisoning by dioxin has not been developed, therefore, carried out mainly symptomatic therapy depending on the intoxication syndrome. To increase the immunological reactivity of the organism using levamisole (see Lagadere. "Dioxins as environmental hazard: retrospective and perspectives". - M.: Nauka. - 1993. - p.142). However, symptomatic treatment of dioxin intoxication ineffective. The situation is getting worse by the fact that as long as n is known, none of the drug, able to destroy or securely display dioxin from the body.

The aim of the invention is to increase the effectiveness of treatment for poisoning animals dioxin.

This objective is achieved in that in case of poisoning of animals by dioxin them daily with drinking water give dimefest at a dose of 50-150 mg/kg body weight daily for 10-30 days.

Dimefest - dimethyl ether, 1,1-dimethyl-3-oxobutyl phosphonic acid produced for medical purposes in the form of a 15%aqueous solution, is a transparent or slightly opalescense liquid with a peculiar odor and bitter taste, the solution pH from 2.0 to 4.0. It is used in pathological conditions involving acidotic shifts in an organism, inflammatory and allergic diseases of the skin and mucous membranes, acute respiratory diseases, chronic nonspecific lung diseases (see Medmaravis. "Drugs". - M.: Medicine. - 1993. - part 2. - S-140).

therapeutic effectiveness of dimefosfona experienced on white rats and rabbits with acute and chronic oral priming animals 2,3,7,8-tetrachlorodibenzo-p-dioxin. Observation of animals were conducted during the period of seed, and then within 30 days after the end of the seed.

Example 1. The proposed method of treatment timeposted the course of the Yong in experiments on rats. The experiments were carried out on white rats weighing 180-210 g, divided into several groups. The first group served as control animals in this group were intragastrically injected oil solution of dioxin dose LD50(61 µg/kg body weight). The second group of animals after a single dose of dioxin treated by timeposted daily was given in drinking water for 30 days at the rate of 50 mg/kg of body weight per day. In the third group in comparison studied therapeutic efficacy of levamisole (prototype), which is recommended for use as immuno-modulator (see Fghnav, Renommee. Drugs for veterinary use". - Kazan. - 2000. - 2 hours. - P.6).

Drug white rats were injected subcutaneously at a dose of 2.5 mg/kg of body weight once a day for 3 days. After a 5 day break, the treatment was repeated twice.

Animals of the fourth group after a dose of dioxin dose LD50were treated with sodium thiosulfate, which is used in veterinary medicine as an anti-inflammatory and antitoxic agent. Sodium thiosulfate was added to the water at the rate of 0.5 g/kg of animal body weight per day.

In the study of animals took into account the General condition, with respect to forage and water, the condition of the mucous membranes and hair coat, body weight, time of death or recovery of the animals.

Re ulitity experiments to study therapeutic effectiveness of drugs listed in the table.

Table
The effectiveness of various methods of treatment in case of poisoning white rats dioxin
Groups of animalsThe number of animals that goal.Time of death, day In brackets the number of dead animals
OnlySurvivedPalo
The seed dioxin48222614(2), 21(3), 23(2), 26(1), 28(2), 35(2), 37(4), 39(10)
Dioxin + dimefest48361228(2), 30(3), 34(4), 35(3)
Dioxin + levamisole48232510(1), 22(3), 24(2), 27(3), 28(2), 30(4), 34(8), 36(1), 38(1)
Dioxin + sodium thiosulfate48242410(1), 23(2), 25(3), 26(4), 28(5), 30(4), 35(3), 36(2)

The table shows that in case of poisoning white rats dioxin dose of 61 ug/kg death of animals was started on the 14th day after injection of poison and lasted for 39 days. Just fell 26 white rats 48, the survival rate was 46%.

Treatment of animals with levamisole was not effective enough, while Palo 25 rats of the 48 that were on the level of control (the ez treatment). Use for treatment of animals sodium thiosulfate was also not effective. At the same time of death and the number of dead animals was not significantly different from the control.

In the treatment of white rats by timeposted 48 poisoned animals survived 36, i.e. 75%. Thus, in comparison with animals of other groups, clinical signs of poisoning were developed at a later date, namely, on the 20th day since the introduction of dioxin.

The clinical examination of patients timeposted animals found that weight loss and other signs of poisoning were less pronounced than in untreated or treated with other drugs. Surviving rats looked relatively active, willingly took food and water.

Example 2. The method of treatment timeposted tested in the seed rabbits dioxin. Animals were divided into two groups. Rabbits of both groups were given within 10 days of food oil solution of dioxin dose of 3 mg/kg of body weight, which was 1/10 LD50. The first group of animals served as control and treatment were not exposed. The second group of animals (experienced) along with seed dioxin daily for 10 days was drinking dimefest at a dose of 100 mg/kg of body weight.

Determination of the clinical status of animals and the study of blood on the content of erythrocytes, hemoglobin, leukocytes, is BEGO protein and its fractions was carried out before the beginning of the seed and then at 10, 20, 30, 50 and 60 days. At the same time determined the phagocytic activity of leukocytes, leukocyte formula, lysozyme activity in control and experimental animals in comparison.

Daily oral administration of dioxin dose of 1/10 LD50the first signs of poisoning in the form of a General depression, loss of appetite, lethargy appeared in control animals on the 10-12 days from the beginning of seed in subsequent intoxication symptoms disappeared. In the experimental animals treated with dimefest, external symptoms were absent.

In control rabbits, untreated, there was a decrease in the number of erythrocytes at 20, 30, 50 and 60 th day from the beginning of the seed 22, 32, 14, and 23%, the content of hemoglobin in these terms was reduced by 16, 19, 7 and 14%. In treated animals, the content of erythrocytes and hemoglobin fluctuated at the level of the background values.

Control animals there was a decrease in the number of cells 20, 30 and 50 day 15, 23 and 24%, while the reduction in these terms was due to the reduction of band neutrophils. In the experimental animals the reduction in the number of cells was less pronounced and at 30 and 60 days was 13 and 11%.

In the experimental animals, poisoned by dioxin and receiving dimefest, on the 10th day there was an increase in phagocytic activity of leukocytes by 89%, while to the to the untreated control animals, it was reduced by 10%.

Control animals after priming the dioxin content of total protein and albumin ranged from background levels. In the experimental animals treated with timeposted, increased total protein content on the 20th and 30th day of 3 and 15%, albumin - 14 and 20%, indicating a positive effect of drug treatment on protein liver function.

When the seed rabbits dioxin dose of 1/10 LD50in untreated animals showed a decrease in the number of γ-globulin 20, 30, 50 and 60 days at 35, 46, 50 and 58%, respectively. In the experimental animals treated with dimefest, decreased concentration γ-globulin was less pronounced. In the subsequent recovery of maintenance γ-globulin in the experimental animals was significantly faster than the control. So, 50 and 60 days decreased concentration γ-globulin in control animals was 50 and 58%have experienced - 22 and 21%, i.e. twice less than that of the untreated.

Example 3. Study of the efficiency of the method of application of dimefosfona on the reproductive function of animals in case of poisoning by dioxin.

Experiments carried out on white rats, which were divided into 3 groups. Animals of the control group of 10 animals was given with food daily oil solution of dioxin dose of 0.3 µg/kg body weight 1 to day 17 of pregnancy. the animals of the experimental group along with seed dioxin daily drinking water dimefest at a dose of 150 mg/kg of body weight. The third group of animals served as biological control, they are the seed had not been exposed to them daily in the feed was added the appropriate dose of vegetable oil used as solvent dioxin.

On the 20th day of pregnancy were killed 5 rats from each group for the study of embryotoxic and teratogenic effects of dioxin and possible corrective effect of dimefosfona.

From poisoned by dioxin animals (without treatment) postimplantation destruction of embryos was 21.6%in treated animals of 11.3%, which is 1.9 times less than in untreated control animals. Total mortality of embryos from poisoned untreated animals amounted to 29.3%in treated - 22%, which is 1.33 times less than in the control group (without treatment).

The mass of the fruit from the poisoned and untreated animals was 8.3% lower than in animals biological control and treated animals fruit weight was lower foetal weight biological control by only 2%.

Thus, the technical result of the invention is to increase therapeutic efficacy of treatment of dioxin poisoning and reduced embryonic mortality in animals.

The treatment of animals in case of poisoning by dioxin, characterized by the fact that they daily drinking water give dimefest at a dose of 50-150 mg/kg of body weight per day in ECENA 10-30 days.



 

Same patents:

FIELD: medicine, toxicology.

SUBSTANCE: invention proposes applying 15% aqueous solution of 1-methyl-5-[2'-(benzyldimethylammonio)ethyl]carbamoyl pyridinium-2-aldoxime dichloride that exceeds the 15% solution of dipiroxime (TMB-4, trimedoxime bromide) used in native medicinal practice by the curative effectiveness. Invention can be used in urgent treatment of acute poisoning with organophosphorus poisonous substances eliciting neuroparalytic effect.

EFFECT: enhanced effectiveness, valuable medicinal properties of agent.

3 tbl

The invention relates to the field of organic chemistry and medicine and relates to a derivative of imidazo-[1,2-a]-benzimidazole, specifically: 9-diethylaminoethyl-2-(3,4-dioksifenil)-imidazo-[1,2-a]-benzimidazole of dihydrobromide formula (I) providing cerebroprotective effect in radiation damage

The invention relates to organic chemistry, in particular to derive SIM-triazine-2-ethylamino-4-piperidyl-6-[(4’-methylcarbamyl-5’-methyl-1’,2’,3’,-triazole)-1-yl]-1,3,5-triazine structure:

as an antidote from fetotoksicheskoe action of the herbicide 2,4 - dichlorophenoxyacetic acid on the sunflower sprouts
Drug // 2229882
The invention relates to a new combination drug, which can be used as a means of protecting the person from the early transient incapacitation and edema of the primary reaction to radiation

The invention relates to new stable crystalline calcium or magnesium salts of (6R,S),(6S) - or (6R)-tetrahydrofolate acid, method for their production and pharmaceutical compositions based on them

FIELD: medicine, toxicology.

SUBSTANCE: treatment is carried out for 2 steps wherein in the first step the preparation xydofone is administrated in the dose 10-20 mg per kg of body mass per 24 h by continuous course for 21-30 days, and in the second step the chelate-forming pharmaceutical preparation with the stability constant 15-20 is administrated in the therapeutic doses by fractional schedule for 2-7 days. Invention promotes to the complete elimination of heavy metal salts from the body due to weakly or strongly fixed ions of heavy metals providing by the successive administration of xydofone and the chelate-forming pharmaceutical preparation, and provides membrane-stabilizing effect on renal tissues that, in turn, prevents arising possible iatrogenic complications. Invention can be used in treatment of chronic intoxication with heavy metals.

EFFECT: improved and enhanced effectiveness of treatment.

3 cl, 2 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to pharmaceutically acceptable 2-ethyl-6-methyl-3-oxypyridine salts with organic carboxylic acids of the general formula: (1-V1): wherein R means -CH2OH (I); R means -CH2-COOH (II); R means -(CH2)3-COOH (III); R means -(CH2)4-COOH (IV); R means -CH(OH)-CH(OH)-COOH (V); R means -CH(NH2)-CH2-COOH (VI) possessing with anxiolytic, antidepressive, antihypoxic, anti-amnestic and anti-oxidative activity and showing decreased toxicity. Also, invention relates to a method for preparing salts and pharmaceutical composition.

EFFECT: improved preparing method, valuable medicinal properties of compounds and pharmaceutical composition.

3 cl, 10 tbl, 10 ex

FIELD: medicine, nephrology, immunology.

SUBSTANCE: one should successively intravenously inject pharmacological preparations mildronat and essentiale at the dosage of 5.0 mg/kg body weight 5 times every other 12 h. The innovation enables to carry out simultaneously normalization of immunity disorders, energetic state of erythrocytes and such biochemical values as the content of macroergic compounds, activity of antioxidant system enzymes, concentration of lipid peroxidation products.

EFFECT: higher efficiency of correction.

1 dwg, 1 ex, 1 tbl

FIELD: medicine, pharmacology, organic chemistry.

SUBSTANCE: invention relates to using 2-amino-4-acetyl-8b-hydroxy-3a,8b-dihydrothiazole[5,4-d]indole as a substance protecting body against hypoxia effect. Invention provides enhanced effectiveness of the protection effect.

EFFECT: enhanced effectiveness of effect of agent.

1 tbl, 1 ex

FIELD: medicine, pharmacology, organic chemistry.

SUBSTANCE: invention relates to using 2-amino-4-acetylthiazolo[5,4-d]indole for protection of body against effect of hemic and hypercapnic hypoxia. Invention proves high effectiveness of the protection effect.

EFFECT: enhanced effectiveness of agent.

2 tbl

FIELD: medicine, medicinal radiobiology, pharmacy.

SUBSTANCE: invention proposes a multicomponent antioxidant complex comprising the following quenching agents of free radicals - ascorbic acid, alpha-tocopherol acetate, retinal acetate, unithiol and sodium selenite as a blocking agent of initiation of free-radical processes. By effect on viability of irradiated animals the invention exceeds the agent-prototype by 2-6 times. In distinction from the prototype, the claimed agent reduces the expression of maximal leukopenia by above two-fold, decreases the concentration of malonic dialdehyde by 1.5-2.0-fold, normalizes the intensity of free-radical oxidation in blood plasma and liver tissue and results to increasing activity of antioxidant systems. Invention can be used in treatment of acute radiation disease.

EFFECT: enhanced and valuable medicinal properties of agent.

6 tbl, 2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used in arresting syndrome of systemic inflammatory response. Agent comprises, mg: diphosphopyridine nucleotide, 0.3-100 and inosine, 40.0-1200. Proposed medicinal agent can comprise additionally inhibitor of angiotensin-converting enzyme, mainly, lisinopril, 2.5-100 and cardiac glycoside, mainly, digoxin, 0.07-0.3. The new medicinal agent possesses the capacity for arresting syndrome of systemic inflammatory response being independently of etiology of its rise, and allows obtaining the expressed and stable curative effect for short times.

EFFECT: improved and valuable properties of medicinal agent.

5 cl, 4 tbl, 4 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to pharmaceutically acceptable salts of 2,4,6-trimethyl-2-hydroxypyridine with lower dicarboxylic acids of the general formulae (1-a-d): possessing an antioxidant activity wherein X means a simple bond (compound 1a), oxalate, C8H11NO x C2H2O4; X means -CH2 (compound 1b), malonate, C8H11NO x C3H4O4; X means -CH2-CH2 (compound 1c), succinate, C8H11NO x C4H6O4); X means the group -CH2CH(OH) (compound 1d), malate, C8H11NO x C4H6O5. Also, invention relates to a pharmaceutical composition of salt of the formula (1c) possessing geroprotecting and anti-ischemic activities, and to a method for preparing these salts.

EFFECT: improved preparing method, valuable medicinal properties of substances and pharmaceutical composition.

3 cl, 5 tbl, 6 ex

FIELD: medicine, food processing industry.

SUBSTANCE: claimed enterosorbent contains 45-80 mass % of polysaccharide and balance: boehmite. As polysaccharide enterosorbent contains chitosan or lignin, or microcrystalline cellulose. Enterosorbent of present invention is useful in excretion of toxic substances from organism, prophylaxis of heavy metal intoxication, etc.

EFFECT: enterosorbent with high adsorption ability in relation to heavy metal ions; application only one kind of polysaccharide.

2 cl, 1 ex, 3 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: claimed method includes blending of active base and auxiliary ingredients to form tablet corn, representing composition of sugar powder, monocrystalline cellulose, vinylpyrrolidone and calcium stearate; humidifying of obtained mixture; drying of obtained granules; dry granulation through granulator with standardized holes; pelletization of standardized granules to produce tablet corn; and coating. Mixture is humidified with 5-7 % starch mucilage in starch mucilage/humidifying mixture mass ratio of 1:25-30, wherein mixture is blending with starch mucilage for homogeneous distribution wet in whole mass.

EFFECT: tablets with increased hardness and enhanced pharmacological activity.

2 cl, 2 ex

FIELD: medicine, toxicology.

SUBSTANCE: treatment is carried out for 2 steps wherein in the first step the preparation xydofone is administrated in the dose 10-20 mg per kg of body mass per 24 h by continuous course for 21-30 days, and in the second step the chelate-forming pharmaceutical preparation with the stability constant 15-20 is administrated in the therapeutic doses by fractional schedule for 2-7 days. Invention promotes to the complete elimination of heavy metal salts from the body due to weakly or strongly fixed ions of heavy metals providing by the successive administration of xydofone and the chelate-forming pharmaceutical preparation, and provides membrane-stabilizing effect on renal tissues that, in turn, prevents arising possible iatrogenic complications. Invention can be used in treatment of chronic intoxication with heavy metals.

EFFECT: improved and enhanced effectiveness of treatment.

3 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with applying biphosphonate for treating osteonecrosis and/or osteonecrosis dissecans. This medicinal preparation could be additionally applied for preventing the development of osteonecrosis and/or osteonecrosis dissecans and any complications associated with both diseases. Biphosphonate acts for the decrease or prevention of severe degree of deformation and/or destruction of a bone or a cartilage and provides the chance to form new bony tissue in a patient.

EFFECT: higher efficiency of therapy.

38 cl, 7 dwg, 1 tbl

FIELD: organic chemistry, medicine, oncology.

SUBSTANCE: invention relates to organic amine salts, amino acid salts and combrestatin A-4 phosphate amino acid ester salts. Invention describes compound of the general formula (I):

wherein one of substitute -OR1 or -OR represents -O-QH+ and another one represents hydroxyl or -O-QH+; Q represents (A) optionally substituted aliphatic organic amine comprising at least one nitrogen atom that in common with proton forms quaternary ammonium cation QH+; (B) amino acid comprising at least two nitrogen atoms wherein one of nitrogen atoms in common with proton forms quaternary ammonium cation QH+; (C) amino acid comprising one or some nitrogen atoms wherein one of nitrogen atoms in common with proton forms quaternary ammonium cation QH+ and wherein, except for, all carboxyl groups of amino acids are in ester form. Also, invention describes pharmaceutical compositions used in modulation of tumor or metastasis proliferation and growth of benign vascular proliferative disorders, using compound of the formula (I) and a method for synthesis of compound of the formula (I). Invention provides preparing new combrestatin A-4 salts showing useful physicochemical properties that enhance solubility of combrestatin A-4.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

27 cl, 13 dwg, 5 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: disclosed are bis(oxymethyl)phosphinic acid salt of formula I and method for production thereof.

EFFECT: antituberculosis agent of decreased toxicity without losses of therapeutic activity.

3 cl, 3 dwg, 9 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with applying a vasculodestroying agent or its pharmaceutically acceptable salt to be introduced for a warm-blooded animal as divided dosages to obtain anti-tumor effect. In particular, a vasculodestroying agent is being ZD6126, AC-7700, combrestatin A4 phosphate or their pharmaceutically acceptable salts. Moreover, total daily dosage of vasculodestroying agent is divided into two or more equal or unequal parts, and interval of time between introduction of every part corresponds to above 0 to about 6 h. The innovation enables to obtain greater anti-tumor effect against the one obtained at introducing the same total dosage of vasculodestroying agent as a single dosage.

EFFECT: higher efficiency of therapy.

18 cl, 2 dwg

Up!